4 completed, 2 terminated, 1 active not recruiting, 1 unknown. 4 Phase 2, 2 Not applicable, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Active not recruiting 1, Terminated 1 |
| Not applicable | 2 | Completed 1, Unknown 1 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
Follow Progesterone Receptor Positive Tumor: new trials by email Literature Review of Progesterone Receptor Positive Tumor trials Research Report on Progesterone Receptor Positive Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression Tamoxifen - Neuroendocrine Tumors, Progesterone Receptor Positive Tumor | Phase 2 | Completed | AC Camargo Cancer Center | 23 | 2019-03-13 | 2024-05-06 |
| A Text-based Intervention in Improving Adherence to Hormone Therapy in Patients With Stage I-III Hormone Receptor Positive Breast Cancer Focus Group, Text Message, Best Practice - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8 | Not applicable | Unknown | Thomas Jefferson University | 332 | 2018-11-07 | 2024-06-10 |
| Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer Palbociclib, Tamoxifen - Hormone Receptor Positive Malignant Neoplasm of Breast, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Phase 2 | Completed | Oana Danciu, MD | 49 | 2017-02-01 | 2026-01-20 |
| Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca Doxorubicin, Cyclophosphamide, Paclitaxel - Breast Adenocarcinoma, Estrogen Receptor- Negative Breast Cancer | Phase 2 | Active not recruiting | Virginia Commonwealth University | 46 | 2017-01-24 | 2026-07-01 |
| A Phase II Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT) DHEA - Metastatic Breastcancer, Estrogen Receptor Positive Breast Cancer | Phase 2 | Terminated | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 20 | 2013-03-01 | 2016-09-29 |
| A Randomised Study of Docosahexaenoic Acid (DHA) in Metastatic Breast Cancer Dietary supplementation with fish oil., Dietary supplementation with vegetable oil - Metastatic Breast Cancer, Progesterone Receptor Positive Tumor | Phase 3 | Terminated | University Hospital, Tours | 65 | 2012-02-01 | 2015-07-29 |
| Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer therapeutic estradiol, exemestane, laboratory biomarker analysis - Estrogen Receptor-positive Breast Cancer, Progesterone Receptor Positive Tumor | Not applicable | Completed | University of Arizona | 13 | 2011-02-01 | 2018-10-17 |
| Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer Exemestane, Laboratory Biomarker Analysis, Oophorectomy - Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor | Phase 3 | Completed | ETOP IBCSG Partners Foundation | 3066 | 2003-12-17 | 2026-08-26 |
Breast Neoplasms (5) · Neuroendocrine Tumors (1) · Triple Negative Breast Neoplasms (1)
Neoplasms (6) · Breast Diseases (5) · Neoplasms by Site (5) · Skin Diseases (5) · Skin and Connective Tissue Diseases (5) · Neoplasms by Histologic Type (1) · Neoplasms, Germ Cell and Embryonal (1) · Neoplasms, Nerve Tissue (1) · Neuroectodermal Tumors (1)
Tamoxifen (3) · exemestane (2) · Albumin-Bound Paclitaxel (1) · Carboplatin (1) · Communication Devices for People with Disabilities (1) · Cyclophosphamide (1) · Decitabine (1) · Dehydroepiandrosterone (1) · Dietary Supplements (1) · Doxorubicin (1) · Enzyme-Linked Immunosorbent Assay (1) · Estradiol (1) · Fish Oils (1) · Focus Groups (1) · Gonadotropin-Releasing Hormone (1)
AC Camargo Cancer Center (1) · ETOP IBCSG Partners Foundation (1) · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS (1) · Oana Danciu, MD (1) · Thomas Jefferson University (1) · University Hospital, Tours (1) · University of Arizona (1) · Virginia Commonwealth University (1)
United States (6) · Brazil (1) · Canada (1) · France (1) · Italy (1) · Switzerland (1)
Elisabetta Pietri, MD (1) · Gini Fleming (1) · Harry D. Bear, M.D., Ph.D. (1) · Jonathan R Strosberg, MD (1) · Kuang-Yi Wen, MD (1) · Oana Danciu, M.D. (1) · Philippe Bougnoux, MD, PhD (1) · Rachel SP Riechelmann, Phd (1) · Robert Livingston (1)
PMID 24095609, PMID 24881463, PMID 25260365, PMID 25495490, PMID 26092816, PMID 27022111, PMID 27044936, PMID 28911092, PMID 29863451, PMID 30591548, PMID 31618131, PMID 36493334, PMID 36521078, PMID 37529158, PMID 40986647, PMID 41637791, PMID 42142667
2004 (1), P30CA016059 (1), P30CA023074 (1), R01CA222246 (1), U24CA075362 (1)